Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has earned a consensus rating of “Buy” from the eleven analysts that are currently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $57.25.

A number of equities analysts have weighed in on SUPN shares. Cantor Fitzgerald reissued a “buy” rating and set a $56.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, September 14th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. Mizuho started coverage on Supernus Pharmaceuticals in a research report on Monday, September 17th. They set a “buy” rating and a $61.00 price target on the stock. Piper Jaffray Companies set a $44.00 price target on Supernus Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, August 28th. Finally, BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, September 19th.

Several institutional investors have recently bought and sold shares of SUPN. FMR LLC grew its position in shares of Supernus Pharmaceuticals by 151.9% in the third quarter. FMR LLC now owns 2,371,321 shares of the specialty pharmaceutical company’s stock valued at $119,396,000 after purchasing an additional 1,430,021 shares during the last quarter. BlackRock Inc. grew its position in shares of Supernus Pharmaceuticals by 8.7% in the second quarter. BlackRock Inc. now owns 7,690,669 shares of the specialty pharmaceutical company’s stock valued at $460,287,000 after purchasing an additional 618,722 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Supernus Pharmaceuticals by 191.3% in the second quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after purchasing an additional 580,990 shares during the last quarter. Macquarie Group Ltd. acquired a new position in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $28,617,000. Finally, Voya Investment Management LLC grew its position in shares of Supernus Pharmaceuticals by 933.5% in the second quarter. Voya Investment Management LLC now owns 585,319 shares of the specialty pharmaceutical company’s stock valued at $35,031,000 after purchasing an additional 528,685 shares during the last quarter. 97.83% of the stock is currently owned by institutional investors.

NASDAQ SUPN traded up $0.42 during trading on Friday, reaching $42.66. 2,641 shares of the company’s stock were exchanged, compared to its average volume of 582,354. The company has a market cap of $2.21 billion, a PE ratio of 33.87 and a beta of 0.92. The company has a quick ratio of 2.65, a current ratio of 2.82 and a debt-to-equity ratio of 0.77. Supernus Pharmaceuticals has a fifty-two week low of $34.90 and a fifty-two week high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.09. The firm had revenue of $102.99 million for the quarter, compared to the consensus estimate of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The business’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 earnings per share. As a group, research analysts anticipate that Supernus Pharmaceuticals will post 1.87 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Article: Stock Symbol

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.